DelMar Pharmaceuticals, Inc. (DMPI)

Unlocking the Promise of Biology DelMar Pharmaceuticals has teamed up with outstanding academic and clinical research institutions from around the world to support the development of our novel cancer therapies.

A First-in-Class Small Molecule DNA-Targeting Agent

VAL-083 is a structurally-unique small molecule, targeting DNA to inhibit cancer cell replication and cell division, leading to cell death. Like other established agents extensively studied by U.S. National Cancer Institute (NCI), such as cisplatin, paclitaxel and camptothecin, VAL-083 has been assessed in 42 Phase 1 and Phase 2 clinical trials sponsored by NCI.